Lyell Immunopharma (LYEL) EPS (Basic) (2020 - 2026)
Lyell Immunopharma (LYEL) posted EPS (Basic) of -$4.72 for Q1 2026, up 44.26% sequentially from -$8.47 in Q4 2025, and up 45.98% YoY from -$3.23 in Q1 2025.
Lyell Immunopharma (LYEL) EPS (Basic) (2020 - 2026) Analysis & Trends
Lyell Immunopharma has reported EPS (Basic) for 7 years, with the latest figure at -$4.72 in Q1 2026.
- Quarterly EPS (Basic) rose 45.98% year-over-year to -$4.72 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$21.28 (up 66.73% YoY) and the FY2025 annual result came in at -$16.76, up 69.47% from the prior year.
- EPS (Basic) rose to -$4.72 in Q1 2026 per LYEL's latest filing, from -$8.47 in the prior quarter.
- Over five years, EPS (Basic) peaked at -$1.1 in Q4 2022 and troughed at -$42.91 in Q4 2024.
- A 5-year average of -$11.12 and a median of -$8.47 in 2025 frame the typical range for EPS (Basic).
- The sharpest annual moves came in 2022 and 2023: EPS (Basic) surged 100.0% in 2022, then sank 2127.98% in 2023.
- Over 5 years, EPS (Basic) stood at -$1.1 in 2022, then tumbled by 2127.98% to -$24.45 in 2023, then slumped by 75.51% to -$42.91 in 2024, then jumped by 80.27% to -$8.47 in 2025, then soared by 44.26% to -$4.72 in 2026.
- According to Business Quant data, EPS (Basic) over the past three periods registered -$4.72, -$8.47, and -$5.59 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | Lyell Immunopharma | 326.39 Mn | 326.39 Mn | - | -4.41 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.41 |
| Mar 31, 2026 | -4.72 |
| Dec 31, 2025 | -8.47 |
| Sep 30, 2025 | -5.59 |
| Jun 30, 2025 | -7.81 |
| Mar 31, 2025 | -8.73 |
| Dec 31, 2024 | -42.91 |
| Sep 30, 2024 | -9.71 |
| Jun 30, 2024 | -10.14 |
| Mar 31, 2024 | -5.89 |
| Dec 31, 2023 | -24.45 |
| Sep 30, 2023 | -5.57 |
| Jun 30, 2023 | -7.26 |
| Mar 31, 2023 | -6.68 |
| Dec 31, 2022 | -1.10 |
| Sep 30, 2022 | -15.17 |
| Jun 30, 2022 | -10.55 |
| Mar 31, 2022 | -14.36 |
| Dec 31, 2021 | -25,944.97 |
| Sep 30, 2021 | -5,066.92 |